Marstacimab significantly reduced annualized bleeding rate by 93% in severe hemophilia A or B patients with inhibitors over 12 months. The treatment is approved in the US and Europe, marking the first ...

Marstacimab is recommended, within its marketing authorisation, as an option for preventing bleeding episodes caused by severe (factor IX [9] activity less than 1%) haemophilia B (congenital factor 9 ...

Pfizer Inc. (NYSE: PFE) disclosed the death of a participant in a long-term open-label extension study of marstacimab in patients with hemophilia A or B. In October 2024, the FDA approved Pfizer’s ...

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today presented results from the pivotal Phase 3 BASIS clinical trial (NCT03938792) evaluating marstacimab for the treatment of people with severe ...

Marstacimab significantly reduced ABR by 93% vs on-demand treatment over 12 months. Topline data were announced from a phase 3 trial evaluating marstacimab for adults and adolescents living with ...

(RTTNews) - Drug major Pfizer Inc. (PFE) announced Tuesday that the pivotal Phase 3 BASIS clinical trial (NCT03938792) evaluating marstacimab has met its primary endpoints, having demonstrated ...

This medication is used by people with a certain inherited bleeding problem (hemophilia A or B) to help prevent or lessen how often you have bleeding problems. Marstacimab belongs to a class of ...

FDA priority review seeks marstacimab label expansion to ≥6 years with inhibitors and ages 6–11 without inhibitors, addressing populations with limited efficacy from factor replacement and high unmet ...

The Medicines and Healthcare products Regulatory Agency (MHRA) has approved the medicine marstacimab (Hympavzi) to prevent or reduce bleeding in patients 12 years of age and older weighing at least 35 ...

There is a simple discount patient access scheme for marstacimab. NHS organisations can get details on the Commercial Access and Pricing (CAP) Portal. Non-NHS organisations can contact ...

Marstacimab reduced annualized bleeding rate by 35% and 92% compared to routine prophylaxis and on-demand treatment in patients with hemophilia A and B without inhibitors, respectively Consistent ...